ImmunityBio Secures $100 Million in Financing

MT Newswires Live03-31

ImmunityBio (IBRX) said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.

The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.

Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.

Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.

Shares of ImmunityBio were 6% higher in Tuesday premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623589637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623589637","market":"hk","top_or_hot":-1,"title":"ImmunityBio Secures $100 Million in Financing","media":"MT Newswires Live","content":"<html><body><p> ImmunityBio (IBRX) said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.</p><p>The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.</p><p>Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.</p><p>Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.</p><p>Shares of ImmunityBio were 6% higher in Tuesday premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Secures $100 Million in Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Secures $100 Million in Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-31 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ImmunityBio (IBRX) said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.</p><p>The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.</p><p>Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.</p><p>Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.</p><p>Shares of ImmunityBio were 6% higher in Tuesday premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623589637","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623589637","pubTimestamp":1774959239,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmunityBio  said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.Shares of ImmunityBio were 6% higher in Tuesday premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio获得1亿美元融资","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio (IBRX) said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.Shares of ImmunityBio were 6% higher in Tuesday premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623589637","isCrawlerRequest":true}